Asset Details
Do you wish to reserve the book?
Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response
Do you wish to request the book?
Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response
2025
Overview
Background
Annual flu vaccination is recommended for children with rheumatic diseases. We investigated the cellular and humoral immune response and safety in pediatric patients that received inactivated influenza vaccines.
Methods
This is a comparative study of in 41 children with juvenile idiopathic arthritis (JIA) receiving influenza vaccination while being treated with methotrexate (MTX) or biological therapy. The influenza vaccination was administered as a single dose of trivalent influenza vaccine (TIV). Serological tests to monitor seroconversion and seroprotection were performed at baseline and at 4 as well as 12 weeks after vaccination.
Results
In all of the 41 children with JIA and the 22 healthy children seroconversion and seroprotection were observed for Influenza A. For Influenza B, no adequate seroconversion rates were not detected in any of the groups studied. No significant differences were observed in lymphocyte subpopulations when analysing time points and groups simultaneously. There were no relapses or cases of influenza infection after the vaccination. Our findings do not suggest non-specific immune activation following vaccination based on the distribution and quantity of the lymphocyte subsets that were investigated.
Conclusion
The present study demonstrates adequate seroprotection rates against influenza A in immunosuppressed children with JIA. The trivalent vaccine had good immunogenicity and was safe to use in both JIA treatment groups.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Juvenile - drug therapy
/ Arthritis, Juvenile - immunology
/ B cells
/ Child
/ Children
/ Female
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Influenza Vaccines - administration & dosage
/ Influenza Vaccines - adverse effects
/ Influenza Vaccines - immunology
/ Influenza, Human - immunology
/ Influenza, Human - prevention & control
/ Juvenile idiopathic arthritis (JIA)
/ Male
/ Medicine
/ Methotrexate - therapeutic use
/ Safety
